ClinicalTrials.gg
RecruitingNCT04578613Updated Jun 5, 2023

ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL

A Phase 3 interventional study of ICP-022 and Chlorambucil in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 56 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-05.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2021; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
218
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 108 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China — 39 open to participants now, 60 under way, 19 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · China.

Planned enrollment
23rd of 105
218 · median 89
Started
2021
with 15 others
Phase 3
25 of 108
9 open now
Primary completion
2024-12
later than 12 of 59 live
Registered
48th of 108
by date

Among the 108 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China, this one is the 23rd largest by planned enrollment of the 105 interventional ones that give a count, is one of 16 that started in 2021, is one of 25 in phase 3, reaches primary completion later than 12 of the 59 other live ones, and was the 48th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

39 of the 108 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China, or all of them as a file.
02

Study summary

This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of ICP-022 versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic Lymphocytic Leukemia.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male or female, age ≥65 years old or age >18 years old or \<65 years old, age >18 years old or \<65 years old shall meet any of the following criteria simultaneously: A.Disease accumulation score (CIRS) > 6;B. at 30-69 mL/ min (Cockcroft-Gault assessment)
  2. Enhanced computed tomography/magnetic resonance imaging (CT/MRI) detection had : at least one lymph node had a maximum axis of more than 1.5 cm and had a measurable vertical dimension
  3. physical strength score is 0-2.
  4. Expected survival time >6 months.
  5. Voluntary written prior to screening.

Key Exclusion Criteria:

  1. Patients with stroke or intracranial hemorrhage in the first 6 months were randomly assigned.
  2. to ICP-022, nitrogen mustard benzoate, rituximab or any other component of the applicable study drug.
  3. Any mental or cognitive impairment that may limit their understanding of the informed consent, their implementation and their compliance with the study.
  4. Pregnant and lactating women, or subjects of childbearing age who do not want to use within 180 days from the end of the study period to the end of the study period.
  5. Conditions in which a potentially life-threatening illness or severe organ dysfunction is not considered appropriate by the investigator.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
218 participants (estimated)

Study arms

  • Experimental
    ICP-022

    ICP-022 will be orally administered until disease progression or unacceptable toxicity.

    Drug: ICP-022

  • Active comparator
    Chlorambucil combined with Rituximab

    Chlorambucil orally administered and Rituximab via IV infusion for 6 cycles.

    Drug: Chlorambucil · Drug: Rituximab

Interventions

  • ICP-022 at a dose of 150mg, QD

  • 0.5 mg/kg body weight orally on Day 1 and Day 15 of Cycles 1-6

  • 375 mg/m2 IV infusion on Day 1 of Cycle 1. 500 mg/m2 IV infusion on Day 1 for each of subsequent cycles (Cycles 2-6)

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    Progress-free survival (PFS) was evaluated by the independent review board (IRC) against the IWCLL2018 criteria (Hallek et al., 2018) and the revised lymphoma mitigation assessment criteria (Cheson et al., 2014).

    Time frame: Up to 5 years

Secondary outcomes

  1. Objective Response Rate (ORR)

    Time frame: Up to 5 years

  2. Duration Of Response (DOR)

    Time frame: Up to 5 years

  3. Overall Survival (OS)

    Time frame: Up to 5 years

07

Study locations

24 of 56 sites recruiting
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui, China
    Not yet recruiting
    • Yanli Yang · Contact
  • Anhui Provincial Cancer Hospital
    Hefei, Anhui, China
    Not yet recruiting
    • Kaiyang Ding · Contact
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui, China
    Not yet recruiting
    • Qingshu Zeng · Contact
  • The Fifth Medical Center of PLA General Hospital
    Beijing, Beijing, China
    Not yet recruiting
    • Hang Su · Contact
  • The First Affiliated Hospital of Congqing Medical University
    Chongqing, Chongqing 400000, China
    Not yet recruiting
    • Qing Xiao · Contact
  • The Second Affiliated Hospital of Army Medical University
    Chongqing, Chongqing, China
    Not yet recruiting
    • Qin Wen · Contact
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian, China
    Recruiting
    • Bing Xu · Contact
  • Lanzhou University Second Hospital
    Lanzhou, Gansu, China
    Not yet recruiting
    • Liansheng Zhang · Contact
  • Dongguan People's Hospital
    Dongguan, Guangdong 523058, China
    Not yet recruiting
    • Yirong Jiang · Contact13688967985
  • Cancer Prevention and Treatment Center, Sun Yat-sen University
    Guangzhou, Guangdong, China
    Recruiting
    • Zhongjun Xia · Contact
  • Guangzhou First People's Hospital
    Guangzhou, Guangdong, China
    Recruiting
    • Qingshun Wang · Contact
  • Shenzhen People's Hospital
    Shenzhen, Guangdong, China
    Not yet recruiting
    • Xinyou Zhang · Contact
  • Affiliated Hospital of Guilin Medical College
    Guilin, Guangxi Zhuang Autonomous Region 541000, China
    Not yet recruiting
    • Wenyuan Lin · Contact15878361619
  • Affiliated Hospital of Hebei University
    Baoding, Hebei, China
    Not yet recruiting
    • Luoming Hua · Contact
  • Hebei Medical University Second Hospital
    Shijiazhuang, Hebei h, China
    Recruiting
    • Jinhai Ren · Contact
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
    Recruiting
    • Lihong Liu · Contact
  • Affiliated Tumor Hospital of Harbin Medical University
    Ha'erbin, Heilongjiang, China
    Not yet recruiting
    • Qingyuan Zhang · Contact
  • The first Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan, China
    Not yet recruiting
    • Haiping Yang · Contact
  • First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
    Recruiting
    • Mingzhi Zhang · Contact
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
    Recruiting
    • Keshu Zhou · Contact
  • Henan Province Hospital
    Zhengzhou, Henan, China
    Recruiting
    • Zunmin Zhu · Contact
  • Zhongnan Hospital of WuHan University
    Wuhan, Hubei 430071, China
    Not yet recruiting
    • Fuling Zhou · Contact
  • Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei, China
    Recruiting
    • Guohui Cui · Contact
  • Yichang Central People's Hospital
    Yichang, Hubei, China
    Recruiting
    • Jingming Guo · Contact
  • Yichang First People's Hospital
    Yichang, Hubei, China
    Recruiting
    • Kaibo Gao · Contact
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410000, China
    Not yet recruiting
    • Hongling Peng · Contact
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan, China
    Recruiting
    • Jing Liu · Contact
  • Zhuzhou Central Hospital
    Zhuzhou, Hunan 412007, China
    Not yet recruiting
    • Guoyu Hu · Contact13707333899
  • Jiangsu Province Hospital
    Nanjing, Jiangsu, China
    Recruiting
    • Jianyong Li · Contact
    • Wei Xu · Contact
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu, China
    Not yet recruiting
    • Zhengming Jing · Contact
  • Wuxi People's Hospital
    Wuxi, Jiangsu, China
    Not yet recruiting
    • Xin Zhou · Contact
  • Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu, China
    Not yet recruiting
    • Zhenyu Li · Contact
  • Subei People's Hospital
    Yangzhou, Jiangsu, China
    Not yet recruiting
    • Jian Gu · Contact
  • The First Affiliated Hospital of Gannan Medical College
    Ganzhou, Jiangxi 341004, China
    Not yet recruiting
    • Yijian Chen · Contact13576749402
  • Jiangxi Cancer Hospital
    Nanchang, Jiangxi, China
    Recruiting
    • Yuerong Shuang · Contact
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
    Recruiting
    • Fei Li · Contact
  • Shengjing Hospital of China Medical University
    Dalian, Liaoning, China
    Recruiting
    • Wei Yang · Contact
  • The First Affiliated Hospital of China Medical University
    Shenyang, Liaoning, China
    Not yet recruiting
    • Yan Li · Contact
  • Affiliated Hospital of Binzhou Medical College
    Binzhou, Shandong, China
    Recruiting
    • Wenzheng Yu · Contact
  • Shandong Cancer Hospita
    Jinan, Shandong 250117, China
    Not yet recruiting
    • Zengjun Li · Contact13642138692
  • Shandong Provincial Hospital
    Jinan, Shandong, China
    Recruiting
    • Xin Wang · Contact
  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai 200025, China
    Not yet recruiting
    • Jianqing Mi · Contact
  • The Second Affiliated Hospital of Xi´an Jiaotong University
    Xi'an, Shanxi 710000, China
    Not yet recruiting
    • Aili, He · Contact
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan, China
    Recruiting
    • Xiaobing Huang · Contact
  • West China Hospital of Sichuan University
    Chengdu, Sichuan, China
    Not yet recruiting
    • Ting Niu · Contact
  • Yibin Second People's Hospital
    Yibin, Sichuan, China
    Recruiting
    • Shihua Huang · Contact
  • General Hospital of Tianjin Medical University
    Tianjin, Tianjin, China
    Recruiting
    • Rong Fu · Contact
  • Hospital of Hematology, Chinese Academy of Medical Sciences
    Tianjin, Tianjin, China
    Recruiting
    • Lugui Qiu · Contact
    • Shuhua Yi · Contact
  • Tianjin Cancer Hospital
    Tianjin, Tianjin, China
    Recruiting
    • Lihua Qiu · Contact
    • Yafei Wang · Contact
  • The First Affiliated Hospital of Xinjiang Medical University
    Ürümqi, Xinjiang Uygur Autonomous Region 830011, China
    Not yet recruiting
    • Jianhua Qu · Contact
  • The first Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan, China
    Not yet recruiting
    • Yun Zeng · Contact
  • Dongyang People's Hospital
    Dongyang, Zhejiang 322199, China
    Not yet recruiting
    • Gongqiang Wu · Contact13757950788
  • Shaoyifu Hospital Affiliated to Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310026, China
    Not yet recruiting
    • Jin Zhang · Contact
  • The First Affiliated Hospital of Zhejiang University Medical College
    Hangzhou, Zhejiang, China
    Recruiting
    • Jie Jin · Contact
  • Jinhua Central Hospital
    Jinhua, Zhejiang 321000, China
    Not yet recruiting
    • Huixian Hu · Contact13588652288
  • Ningbo First Hospital
    Ningbo, Zhejiang, China
    Not yet recruiting
    • Guifang Ouyang · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Dec 2024, 47 months after the start.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's planned 47 months is below that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2020
First posted
Oct 8, 2020
StartActual
Jan 8, 2021
Primary completionEst.
Dec 30, 2024
CompletionEst.
Jun 30, 2025
Last update
Jun 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04578613
Responsible party
Sponsor
First posted
Oct 8, 2020
Start date
Jan 8, 2021
Primary completion
Dec 30, 2024 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Jun 5, 2023

Study contacts

April Huang
Contact
April.huang@innocarepharma.com
010-66609723

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orelabrutinib

Start the discussion